Prostatype Genomics AB (publ)

Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.

Prostatype Genomics AB (publ) trades as PROGEN.ST on STO. The company is classified in Healthcare / Medical - Diagnostics & Research and reports in SEK.

The current profile places the business in Medical - Diagnostics & Research. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Prostatype Genomics AB (publ) can be compared against peers such as 2cureX AB (publ), Aino Health AB (publ), Aptahem AB (publ), Chordate Medical Holding AB (publ), Episurf Medical AB (publ), Fluicell AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $13.63M, beta of 1.48, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

PROGEN.ST currently shows total debt of N/A and beta of 1.48. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.prostatypegenomics.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.